Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Lippincott Williams & Wilkins
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
[Abstract Not Available]
Açıklama
Anahtar Kelimeler
DLBCL, Zilovertamab Vedotin (MK 2140), Relapsed/Refractory (R/R)
Kaynak
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
WoS Q Değeri
Q1
Scopus Q Değeri
N/A
Cilt
41
Sayı
16
Künye
Özcan, M., Lee, S. T., Mensah, F., Modi, D., Fossa, A., Kim, W. S. ... Lavie, D. (2023). Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 41(16). Chicago, IL, 02-06 June, 2023.
